Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/3/2025 | $60.00 | Peer Perform → Outperform | Wolfe Research |
| 9/12/2024 | $42.00 | Equal Weight | Wells Fargo |
| 8/27/2024 | $55.00 | Buy | Redburn Atlantic |
| 8/6/2024 | $46.00 → $44.00 | Overweight → Neutral | JP Morgan |
| 1/19/2024 | $40.00 → $41.00 | Buy → Neutral | Citigroup |
| 1/4/2024 | $42.00 | Market Perform | TD Cowen |
| 11/29/2023 | $32.00 | Outperform → In-line | Evercore ISI |
| 10/5/2023 | Peer Perform | Wolfe Research |
NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Carlyle Secured Lending, Inc. (together with its consolidated subsidiaries, "we," "us," "our," "CGBD" or the "Company") (NASDAQ:CGBD) today announced its financial results for its fourth quarter and full year ended December 31, 2024. Justin Plouffe, CGBD's Chief Executive Officer said, "CGBD produced a strong finish to 2024 with portfolio growth driven by fourth quarter net investment activity. Net investment income remained comfortably above our base dividend and consistent with the prior quarter, despite tightening market spreads and continued repricing activity. We are very pleased with our performance throughout the fourth quarter and 2024 br
CONSHOHOCKEN, Pa., Feb. 24, 2025 /PRNewswire/ -- NSM Insurance Group ("NSM"), a global specialty insurance provider, announced today it has signed a definitive agreement to sell its U.S. commercial insurance division to New Mountain Capital ("New Mountain"), a leading growth-oriented investment firm with over $55 billion in assets under management. The transaction is expected to close in the next 45 days. The closing is subject to regulatory approvals and other customary closing conditions. NSM is a portfolio company of global investment firm Carlyle. "Today, we are excited fo
bluebird stockholders to receive $3.00 per share in cash and a contingent value right of $6.84 per share in cash payable upon achievement of a net sales milestone, contingent upon offer conditions bluebird's Board of Directors determined this transaction is in the best interest of stockholders following a comprehensive review of strategic alternatives Carlyle and SK Capital, in collaboration with a team of highly experienced biotech executives led by David Meek, to support bluebird's growth bluebird bio, Inc. (NASDAQ:BLUE) ("bluebird") today announced that it has entered into a definitive agreement to be acquired by funds managed by global investment firms Carlyle (NASDAQ:CG) and SK Capi
4 - Carlyle Group Inc. (0001527166) (Issuer)
4 - Carlyle Group Inc. (0001527166) (Issuer)
4 - Carlyle Group Inc. (0001527166) (Issuer)
10-K - Carlyle Group Inc. (0001527166) (Filer)
13F-HR - Carlyle Group Inc. (0001527166) (Filer)
13F-HR - Carlyle Group Inc. (0001527166) (Filer)
Wolfe Research upgraded Carlyle Group from Peer Perform to Outperform and set a new price target of $60.00
Wells Fargo initiated coverage of Carlyle Group with a rating of Equal Weight and set a new price target of $42.00
Redburn Atlantic initiated coverage of Carlyle Group with a rating of Buy and set a new price target of $55.00
SC 13D/A - Carlyle Group Inc. (0001527166) (Subject)
SC 13D/A - Carlyle Group Inc. (0001527166) (Filed by)
SC 13D/A - Carlyle Group Inc. (0001527166) (Filed by)
MCLEAN, Va., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Acentra Health, a technology and health solutions and services company dedicated to accelerating better outcomes for its government and commercial healthcare clients and the populations they serve, today announced the appointment of Calder Lynch and Jami Snyder to its healthcare advisory board. With decades of experience leading state and federal government healthcare programs, the subject matter experts will advise the company and its clients on healthcare policies and trends as well as strategies to improve health outcomes at a lower cost. "We are excited to welcome Calder Lynch and Jami Snyder to Acentra Health's Healthcare Advisory Boar
MCLEAN, Va., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Acentra Health, a technology and health solutions and services company dedicated to accelerating better outcomes for its government and commercial healthcare clients and the populations they serve, announced it has appointed Ezmeralda Sager as Executive Vice President and Chief Transformation Officer (CTO), effective January 6, 2025. In this role, Sager will spearhead enterprise-wide change initiatives to help Acentra Health build upon its strong track record of innovation and execution for its clients. She will provide strategic guidance on process improvements to optimize the development and delivery of the company's products, solutions
London, UK and New York, USA, September 10, 2024 - Abingworth, a leading transatlantic life sciences investment firm and part of global investment firm Carlyle (NASDAQ:CG), today announced the appointment of Robert (Bob) DeBenedetto as Managing Director – Clinical Co-Development. Bob brings to Abingworth over 30 years of experience in the life sciences industry and will be working on Clinical Co-Development deals and execution with new and existing Abingworth portfolio companies. He will be based in Abingworth's Menlo Park, CA, USA office. Prior to joining Abingworth, Bob was the Founder, President and CEO of SFJ Pharmaceuticals Inc. (CA, USA), an Abingworth portfolio company, where he
NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Carlyle Secured Lending, Inc. (together with its consolidated subsidiaries, "we," "us," "our," "CGBD" or the "Company") (NASDAQ:CGBD) today announced its financial results for its fourth quarter and full year ended December 31, 2024. Justin Plouffe, CGBD's Chief Executive Officer said, "CGBD produced a strong finish to 2024 with portfolio growth driven by fourth quarter net investment activity. Net investment income remained comfortably above our base dividend and consistent with the prior quarter, despite tightening market spreads and continued repricing activity. We are very pleased with our performance throughout the fourth quarter and 2024 br
NEW YORK, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Carlyle Credit Income Fund ("we," "us," "our," "CCIF" or the "Fund") (NYSE:CCIF) announced today that it will release financial results after market close on Wednesday, February 26, 2025, for its first quarter of 2025. CCIF will host a conference call at 10:00 a.m. EDT on Thursday, February 27, 2025, to discuss the results. The conference call will be available via public webcast via a link on Carlyle Credit Income Fund's website at www.carlylecreditincomefund.com and will also be available on the website soon after the call's completion. About Carlyle Credit Income Fund Carlyle Credit Income Fund (NYSE:CCIF) is an externally managed clo
NEW YORK, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Carlyle Secured Lending, Inc. ("Carlyle Secured Lending") (NASDAQ:CGBD) will host a conference call at 11:00 a.m. EST on Wednesday, February 26, 2025 to announce its financial results for the fourth quarter and full year ended December 31, 2024. A news release containing the quarterly results will be issued on Tuesday, February 25, 2025. The conference call will be available via public webcast via a link on Carlyle Secured Lending's website at carlylesecuredlending.com and will also be available on the website soon after the call's completion. About Carlyle Secured Lending, Inc. Carlyle Secured Lending, Inc. is a publicly traded (NASDAQ:CG